World Journal of Surgery

, Volume 29, Issue 3, pp 334–338

Tissue MicroArray Analyses of Pancreatic Duodenal Homeobox-1 in Human Cancers

Authors

  • Xiao-Ping Wang
    • Michael E. DeBakey Department of SurgeryBaylor College of Medicine
  • Zhi-Jun Li
    • Michael E. DeBakey Department of SurgeryBaylor College of Medicine
  • Jonas Magnusson
    • Michael E. DeBakey Department of SurgeryBaylor College of Medicine
  • F. Charles Brunicardi
    • Michael E. DeBakey Department of SurgeryBaylor College of Medicine
Article

DOI: 10.1007/s00268-004-7823-4

Cite this article as:
Wang, X., Li, Z., Magnusson, J. et al. World J. Surg. (2005) 29: 334. doi:10.1007/s00268-004-7823-4

Abstract

In previous studies, we demonstrated that rat insulin promoter (RIP)-driven gene therapy successfully targeted human pancreatic tumor PANC-1 cells and mouse insulinoma NIT-1 cells, which are both pancreatic duodenal homeobox-1 (PDX-1)-positive. The purpose of this study was to perform a human tissue array analysis to determine potential targets for RIP-driven gene therapy. A custom-designed tissue MicroArray analysis of various human cancer specimens was performed using a PDX-1 polyclonal antibody generated in our laboratory. The custom-designed Tissue MicroArray of human tumor specimens consists of human cancer specimens from different origins, such as the pancreas, breast, colon, prostate, kidney, liver, lung, and ovary. A panel of normal human specimens from 20 organs or tissues was used as a control. All tissues were fixed in formalin and embedded in paraffin. The immunohistochemistry studies of the cytoplasm and the nuclear expression levels were compared using the Loda method and blind reviews. Data are presented as the mean ± SEM (p < 0.05 was considered significant by the unpaired student t-test). PDX-1 expression intensity was elevated in both benign and malignant tissues from the same patient with pancreas, breast, colon, prostate, and kidney cancers, whereas normal human tissues from control subjects without cancer did not express PDX-1. These results suggest that PDX-1 is an early marker for these cancers and could be potentially used as a diagnostic parameter and perhaps could be targeted by PDX-1-activated gene therapies, such as RIP-TK.

Copyright information

© Société Internationale de Chirurgie 2005